Off-label use | Anticancerfund

Off-label use

Off-label use is when an approved pharmaceutical drug is used for an unapproved indication, in an unapproved patient group or dosage, or via an unapproved administration route.

The untapped potential of marketed drugs

Cancer therapies should be evaluated for their full potential, including their efficacy against less common or other cancer types. Adding new indications to existing treatments requires additional research and trials. This costs money, but the process is much faster than de novo drug development, as costly investigations such as those concerning safety and toxicity do not need to be repeated for an approved drug.

Off label icon

Off-label use in cancer treatment

Off-label drug use is common in cancer treatment, because:

  • many cancer drugs are effective against more than one cancer type;

  • more than one approved therapy may be involved, even though the combination of therapies is not approved;

  • research uncovers new uses for drugs that are already approved for other uses;

  • patients have exhausted all other approved options, as is often the case in rare cancers.

Difficulties of off-label use

Off-label use can complicate health insurance coverage and reimbursements and puts the prescribing practitioner at a high level of clinical responsibility, as it is the practitioner that must approve off-label use. Because these drugs are not officially indicated for a specific disease, the patient often pays full price. Even more, there is a possibility that the producing company might take it off the market when the drug is no longer needed for its official indication.

Off-label use is not without any danger. It could be harmful if:

  • There is  limited evidence that the drug is effective against a specific type of cancer;

  • potential benefits are outweighed by the risks of giving the drug.

ACF’s view on off-label use

The Anticancer Fund strives to provide more evidence for off-label drugs by performing drug repurposing trials. To minimise the difficulties and dangers of off-label use, it is optimal for a drug to be officially registered after clinical trials provide evidence of its effectiveness.

ACF’s view on off-label use